Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: A short-term, randomized, controlled trial

Journal of the American Society of Nephrology

Volumn 16, Issue 7, 2005, Pages 2119-2126

  Navarro, Juan F ^a,b   Mora, Carmen ^a,b   Muros, Mercedes ^a,b   García, Javier ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b CSIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; IRBESARTAN; LOSARTAN; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; URINARY TRACT AGENT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DIZZINESS; DRUG EFFECT; DYSPEPSIA; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RENAL PROTECTION; DRUG POTENTIATION; MIDDLE AGED; URINE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG SYNERGISM; FEMALE; HUMANS; MALE; MIDDLE AGED; PENTOXIFYLLINE; PROTEINURIA; RENAL AGENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27744600400     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005010001     Document Type: Article

References (63)

1. Remuzzi G, Ruggenenti P, Benigni A: Understanding the nature of renal disease progression. Kidney Int 51: 2-15, 1997
2. Bloomgarden ZT: Perspectives on the news: American Diabetes Association Annual Meeting 1999. Diabetes Care 23: 845-852, 2000
3. Pickup J, Mattock M, Chusney G, Burt D: NIDDM as a disease of the innate immune system: Association of acutephase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40: 1286-1292, 1997
4. Pickup J, Chusney G, Thomas S, Burt D: Plasma interleukin-6, tumor necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 67: 291-300, 2000
5. Chen J, Gall M, Yokoyama H, Jensen J, Deckert M, Parving HH: Raised serum sialic acid concentrations in NIDDM patients with and without diabetic nephropathy. Diabetes Care 19: 130-134, 1996
6. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy R, Haffner S: Inflammation and microalbuminuria in non-diabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 58: 1703-1710, 2000
7. Navarro JF, Mora C, Macía M, García J: Inflammatory parameters are independently associated with urinary albumin excretion in type 2 diabetes mellitus. Am J Kidney Dis 42: 53-61, 2003
8. Navarro J: Diabetic nephropathy: A matter of inflammation? Nefrologia 23: 381-389, 2003
9. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH: Progression of diabetic nephropathy. Kidney Int 59: 702-709, 2001
10. Parving HH: Renoprotection in diabetes: Genetic and non-genetic risk factors and treatment. Diabetologia 41: 745-759, 1998
11. De Jong PE, Navis GJ, De Zeeuw D: Renoprotective therapy: Titration against urinary protein excretion. Lancet 354: 352-353, 1999
12. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group: Renoprotective effects of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
13. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
14. Hostetter TH: Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 345: 910-912, 2001
15. Ward A, Clissold SP: Pentoxifylline: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34: 50-97, 1987
16. Tripathy K, Prakash J, Appaiha D, Srivastava PK: Pentoxifylline in management of proteinuria in diabetic nephropathy. Nephron 64: 641-642, 1993
17. Guerrero-Romero F, Rodríguez-Morán M, Paniagua-Sierra J, García-Bulnes G, Salas-Ramírez M, Amato D: Pentoxifylline reduces proteinuria in insulin-dependent and non-dependent diabetic patients. Clin Nephrol 43: 116-121, 1995
18. Navarro J, Mora C, Muros M, Macía M, García J: Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: A short-term, prospective, randomised study. Am J Kidney Dis 42: 264-270, 2003
19. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Macía M, Mendez ML, García J: Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: Effects of pentoxifylline administration. Am J Kidney Dis 33: 458-463, 1999
20. Parving HH, Andersen AR, Smidt UM, Svendsen PA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1: 1175-1179, 1983
21. Mogensen CE, Chachati A, Christensen CK, Close CF, Deckert T, Hommel E, Kastrup J Lefebvre P, Mathiesen ER, Feldt-Rasmussen B: Microalbuminuria: An early marker of renal involvement in diabetes. Uremia Invest 9: 85-95, 1985
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999
23. Rossing P, Hommel E, Smidt UM, Parving HH: Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37: 511-516, 1994
24. Harmankaya O, Seber S, Yilmaz M: Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail 25: 465-470, 2003
25. Bacher A, Mayer N, Klimscla W, Oismuller C, Stelzer H, Hammerle A: Effects of pentoxifylline on hemodynamics and oxygenation in septic and nonseptic patients. Crit Care Med 25: 795-800, 1997
26. Solerte S, Fioravanti M, Bozzetti, Schifino N, Parti A, Fedele P, Viola C, Ferrari E: Pentoxifylline, albumin excretion rate and proteinuria in type I and type II diabetic patients with microproteinuria. Results of a short-term randomized study. Acta Diabetol Lat 23: 171-177, 1986
27. Skudicky D, Bergemann A, Sliwa K, Candy G, Saveli P: Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: Results of a randomized study. Circulation 103: 1083-1088, 2001
28. Frantz RP, Edwards B, Olson L, Schwab M, Adams T, Textor S, Daly R, McGregor C, Rodeleffer R: Effects of pentoxifylline on renal function and blood pressure in cardiac transplant recipients: A randomized trial. Transplantation 63: 1607-1610, 1997
29. Katsuki A, Sumida Y, Murashima S, Murata K, Takarada Y, Ito K, Fujii M, Tsuchihashi K, Nakatami K, Yano Y: Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 83: 859-862, 1998
30. Abdella N, Akanji A, Mojiminiyi O, Al Assoussi A, Moussa M: Relation of serum total sialic acid concentrations with diabetic complications and cardiovascular risk factors in Kuwaiti type 2 diabetic patients. Diabetes Res Clin Pract 50: 65-72, 2000
31. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, Cavallo Perin P; Casale Monferrato Study: Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 26: 2150-2155, 2003
32. Kalantarinia K, Awas AS, Siragy HM: Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int 64: 1208-1213, 2003
33. Dipetrillo K, Coutermarsh B, Gesek FA: Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 284: F113-F121, 2003
34. Sassy-Prigent C, Heudes D, Mandet C, Belair MF, Michel O, Perdereau B, Bariety J, Bruneval P: Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 49: 466-475, 2000
35. Young Ba, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG, Seidel K: Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 47: 935-944, 1995
36. Cortes P, Zhao X, Riser BI, Narins RG: Role of glomerular mechanical strain in the pathogenesis of diabetic nephropathy. Kidney Int 51: 57-68, 1997
37. Hasegawa G, Nakano K, Manabu S, Uno K, Shibayama Y, Ienaaga K, Kondo M: Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40: 1007-1012, 1991
38. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, Koide H: mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42: 450-456, 1993
39. Sugimoto H, Shikata K, Wada J, Horiuchi S, Makino H: Advanced glycation end products-cytokine oxide sequence pathway in the development of diabetic nephropathy: Aminoguanidine ameliorates the overexpression of tumour necrosis factor-alpha and inducible nitric oxide synthase in diabetic rat glomeruli. Diabetologia 42: 878-886, 1999
40. Dipetrillo K, Gesek FA: Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol 24: 352-359, 2004
41. Bertani T, Abbate M, Zoja C, Corna D, Perico N, Ghezzi P, Remuzzi G: Tumor necrosis factor induces glomerular damage in rabbit. Am J Pathol 134: 419-430, 1989
42. Ortiz A, Gonzalez-Cuadrado S, Bustos C, Alonso J, Gonmez-Guerrero C, Lopez-Armada MF, Gonzalez E, Plaza JJ, Egido J: Tumor necrosis factor as a mediator of glomerular damage. J Nephrol 8: 27-34, 1995
43. McCarthy E, Sharma R, Sharma M, Li JZ, Ge XL, Dileezpan KN, Savin VJ: TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide. J Am Soc Nephrol 9: 433-438, 1998
44. Shugimoto H, Shikata K, Hirata K, Akiyama K, Matsuda M, Kushiro M, Shikata Y, Miyatake N, Miyasaka M, Makino H: Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: Glomerular hyperfiltration is a potential mechanism of ICAM-1 up-regulation. Diabetes 46: 2075-2081, 1997
45. Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, Schneider H, Ruiz-Ortega M, Egido J: NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19: 2505-2512, 2004
46. Flyvbjerg A, Khatir DS, Jensen LJ, Dagnaes-Hansen F, Gronbaek H, Rasch R: The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. Curr Pharm Des 10: 3385-3394, 2004
47. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998
48. Zoja C, Remuzzi G, Bertani T: Cellular responses to protein overload: Key event in renal disease progression. Curr Opin Nephrol Hypertens 13: 31-37, 2004
49. Remuzzi G, Zoja C, Gagliardini E, Corna D, Abbate M, Benigni A: Combining an antiproteinuric approach with mycophenolate mofetil fully suppress progressive nephropathy of experimental animals. J Am Soc Nephrol 10: 1542-1549, 1999
50. Utimura R, Fujihara CK, Mattar AL, Malheiros DM, Noronha LL, Zatz R: Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int 63: 209-216, 2003
51. Ambrus JL, Anain JM, Anain SM, Anain PM, Anain JM Jr, Stadler S, Mitchel P, Brooks JA, Cobert BL, Savitsky JP: Dose-response effects of pentoxifylline on erythrocyte filterability: Clinical and animal models studies. Clin Pharmacol Ther 48: 50-57, 1990
52. Angielski S, Jakubowski Z, Pawelczyk T, Piec G, Redlak M: Renal handling and metabolism of adenosine in diabetic rats. Contrib Nephrol 73: 52-56, 1989
53. Han J, Thompson P, Beutler D: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signalling pathway. J Exp Med 172: 393-394, 1990
54. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA: Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110: 192-198, 1991
55. Segal R, Dayan M, Zinger H, Mozes E: Supression of experimental systemic lupus erythematous (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxifylline. Lupus 10: 23-31, 2001
56. Chen YM, Ng YY, Lin SL, Chiang WC, Lan HY, Tsai TJ: Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats. Nephrol Dial Transplant 19: 1106-1115, 2004
57. Chen YM, Chien CT, Hu-Tsai MI, Wu KD, Tsai CC, Wu MS, Tsai TJ: Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis. Kidney Int 56: 932-943, 1999
58. Lin SL, Chen YM, Chien CT, Chiang WC, Tsai CC, Tsai TJ: Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J Am Soc Nephrol 13: 2916-2929, 2002
59. Rossing K, Christensen PK, Hansen BV, Carstensen B, Parving HH: Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: A double-blind randomized crossover study. Diabetes Care 26: 150-155, 2003
60. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons for the RENAAL. Kidney Int 65: 2309-2320, 2004
61. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system versus maximal recommended dose inhibition in diabetic nephropathy. Kidney Int 63: 1874-1880, 2003
62. Cetinkaya R, Odabas AR, Selcuk Y: Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes. Int J Clin Pract 58: 432-435, 2004
63. Gorson DM: Reduction of macroalbuminuria with pentoxifylline in diabetic nephropathy. Diabetes Care 21: 2190-2191, 1998